ReviewWiener medizinische Wochenschrift (1946)2015
Efficacy and safety of rituximab in rheumatic diseases.
Review in Wiener medizinische Wochenschrift (1946), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments.Journal of nanobiotechnology · 2023Review
- Biologic therapy in the idiopathic inflammatory myopathies.Rheumatology international · 2020Review
- Genetic and clinical markers for predicting treatment responsiveness in rheumatoid arthritis.Frontiers of medicine · 2019Review
- Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.Endocrine reviews · 2019Review
- Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders.Neurology(R) neuroimmunology & neuroinflammation · 2018Article
- Differences in treatment of anti-NMDA receptor encephalitis: results of a worldwide survey.Journal of neurology · 2017Article
- Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis.ImmunoTargets and therapy · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
B-cell depleting therapy is now in clinical use for more than 10 years in rheumatology. In 2001, a first report was published on five rheumatoid arthritis patients responding to the chimeric anti-CD20 antibody rituximab. Since then, numerous clinical trials, prospective and retrospective studies, registry data as well as case reports on the use of rituximab in autoimmune rheumatic diseases have been published. This review gives a short overview on clinical data of rituximab in rheumatic diseases currently available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.